The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.
March 11, 2011 — A combination of 4 blood proteins may serve as biomarkers to help clinicians distinguish patients with asthma from those with chronic obstructive pulmonary disease (COPD), Australian ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback